|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Product | |||||
| Service | |||||
| Total revenues | |||||
| Cost of revenues | |||||
| Product | |||||
| Service | |||||
| Total cost of revenues | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development (net of grant participations of $ 1,401, $ 1,595 and $ 3,129 for the years ended December 31, 2025, 2024 and 2023, respectively) | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Operating income (loss) | |||||
| Loss from extinguishment | |||||
| Other income | |||||
| Financial income, net | |||||
| Income (loss) before income tax expense | |||||
| Income tax expense | |||||
| Net income (loss) | |||||
| Net loss per share: | |||||
| Basic net income (loss) per share | |||||
| Diluted net income (loss) per share | |||||
| Weighted average number of shares used in per share computations of net loss: | |||||
| Weighted average number of shares used in computations basic net income (loss) | |||||
| Weighted average number of shares used in computations diluted net income (loss) | |||||
| Unrealized gain on available-for-sale marketable securities | |||||
| Net amount reclassified to earnings from available-for-sale marketable securities | |||||
| Total comprehensive gain (loss) from available-for-sale marketable securities | |||||
| Unrealized gain (loss) on foreign currency cash flow hedges transactions | |||||
| Net amount reclassified to earnings from hedging transactions | |||||
| Total comprehensive gain (loss) from hedge transactions | |||||
| Total other comprehensive income (loss) | |||||
| Total comprehensive income (loss) | |||||
Loading...